Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ALS on the Cusp

This article was originally published in Start Up

Executive Summary

Amyotrophic lateral sclerosis, the devastating neurodegenerative disease, has largely defied R&D efforts, but emerging knowledge, much of it through nonprofit research organizations, raises hopes for better results and treatments with blockbuster potential. In this issue we profile two emerging drug developers hoping to make an impact: Cambria Pharmaceuticals and Knopp Neurosciences.

Related Content

Scientific Advances Increase Potential For Drugs To Treat ALS
FDA Finds Statins Not Linked To ALS; When Can A False Alarm Be Turned Off?
Start-Up Previews (07/2008)
Cambria Pharmaceuticals Inc.
Knopp Neurosciences Inc.
Knopp Neurosciences Inc.
Cambria Pharmaceuticals Inc. Social Web Site Is Resource For Drug Market Research
Following Phase II Failure, Teva Drops Investigation Of Glatiramer For ALS


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts